Ocuphire Pharma, Inc. (OCUP)

Ocuphire Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	47.16	50.5	42.63	24.53	16.4	1.54
Short-Term Investments	0.01	0.02	0.05	0.22	0	0
Cash & Cash Equivalents	47.17	50.52	42.68	24.75	16.4	1.54
Cash Growth	20.91%	18.35%	72.44%	50.94%	966.95%	-89.56%
Receivables	3.12	2.33	4.85	0	0	0
Other Current Assets	1.56	1.1	1.45	1.31	1.27	0.23
Total Current Assets	51.84	53.95	48.99	26.07	17.67	1.76
Property, Plant & Equipment	0	0	0.01	0.01	0.01	0.02
Total Long-Term Assets	0	0	0.01	0.01	0.01	0.02
Total Assets	51.84	53.95	48.99	26.08	17.68	1.78
Accounts Payable	2.06	2.15	1.07	1.58	1.21	0.34
Current Debt	0	0	0	0.54	0	5.67
Other Current Liabilities	3.72	1.89	1.68	1.73	1.97	3.34
Total Current Liabilities	5.79	4.04	2.75	3.86	3.19	9.34
Other Long-Term Liabilities	0	0	0	0	27.96	0
Total Long-Term Liabilities	0	0	0	0	27.96	0
Total Liabilities	5.79	4.04	2.75	3.86	31.15	9.34
Total Debt	0	0	0	0.54	0	5.67
Retained Earnings	-88.57	-81.47	-71.48	-89.37	-32.68	-8.06
Shareholders' Equity	46.06	49.91	46.24	22.22	-13.47	-7.56
Net Cash / Debt	47.17	50.52	42.68	24.22	16.4	-4.13
Net Cash / Debt Growth	20.91%	18.35%	76.27%	47.66%	-	-
Net Cash Per Share	1.92	2.34	2.07	1.63	3.52	-1.45
Working Capital	46.06	49.91	46.23	22.21	14.48	-7.58
Book Value Per Share	1.88	2.31	2.32	1.50	-2.89	-2.66

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).